z-logo
open-access-imgOpen Access
T-cell immunity against cytomegalovirus in HIV infection and aging: relationships with inflammation, immune activation, and frailty
Author(s) -
Juliette Tavenier,
Joseph B. Margolick,
Sean X. Leng
Publication year - 2019
Publication title -
medical microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.954
H-Index - 61
eISSN - 1432-1831
pISSN - 0300-8584
DOI - 10.1007/s00430-019-00591-z
Subject(s) - immunology , immune system , inflammation , cytomegalovirus , chronic infection , immunity , medicine , human cytomegalovirus , virus , biology , viral disease , herpesviridae
Both aging and treated human immunodeficiency virus (HIV) infection are characterized by low-level chronic inflammation and immune activation which contribute to the development of age-related diseases, frailty, and early mortality. Chronic cytomegalovirus (CMV) infection is highly prevalent in older adults and HIV-infected populations. A number of studies have shown that CMV induces broad and strong T-cell responses in CMV-seropositive older adults and HIV-infected individuals. CMV infection rarely develops into clinical disease in immunocompetent individuals. However, a large body of literature has shown adverse effects of chronic CMV infection on the health and longevity of these populations. It has been hypothesized that chronic CMV infection may be a driver of chronic inflammation and immune activation, and may further contribute to the development of frailty. Thus, there is a need to better understand the extent of the impact of chronic CMV infection on T-cell immunity and health in aging and HIV infection. In this review, we will address important considerations and challenges in the assessment of chronic CMV infection and CMV-specific T-cell responses. We will then review recent data on relationships between T-cell responses to CMV and levels of inflammatory markers and immune activation, as well as the onset of frailty.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here